G. Yunwen: Radioprotection 2025, 60( 1), 91 – 98 97
Author contribution statement
This paper was solely authored by Ge Yunwen. She was responsible for the conception, design, data collection, analysis, and manuscript writing.
Ethics approval
Ethical approval was not required.
Informed consent The article does not contain any studies involving human subjects.
Supplementary material
Table B3 in GB 18871: provides committed effective dose per unit intake e( g) via inhalation and ingestion for radioactive isotopes. For iodine-131, the value is 7.6 × 10-9, 1.1 × 10-8, and 2.2 × 10-8 Sv / Bq. So, ej should be taken as 2.2 × 10-8 Sv / Bq.
The Supplementary Material is available at https:// www. radio pro-journal. org / 10.1051 / radiopro / 2024042 / olm.
References
Barquero R, Basurto F, Nunez C, et al. 2008. Liquid discharges from patients undergoing 131 Itreatments. J Environ Radioact 99: 1530 – 1534.
China Atomic Energy Agency, Ministry of Science and Technology, Ministry of Ecology and Environment et al. 2021. Medium and longterm development plan for medical isotopes. Available from: https:// www. caea. gov. cn / n6760338 / n6760342 / c6831058 / content. html. Clarke SEM. 1994. Radioiodine therapy of the thyroid. In Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment pp. 833-845. Edinburgh: Churchill Livingstone.
Department of Radiation Source Safety Regulation, Ministry of Ecology and Environment. 2023. Reply to Consultation on Several Clauses of the Nuclear Medicine Standard( Radiation Notice( 2023) 20th). Available from: https:// www. mee. gov. cn / xxgk2018 / xxgk / sthjbsh / 202309 / t20230913 _ 1040761. html [ Reply to Consultation on Several Clauses of the Nuclear Medicine Standard ].
Driver I, Packer S. 2001. Radioactive waste discharge quantities for patients undergoing radioactive iodine therapy for thyroid carcinoma. Nucl Med Commun 22: 1129.
Esser JP, Krenning EP, Teunissen JJM, et al. 2006. Comparison of [( 177) Lu-DOTA( 0), Tyr( 3)] octreotate and [( 177) Lu-DOTA( 0), Tyr( 3)] octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Molec Imag 33: 1346 – 1351.
General Administration of Quality Supervision, Inspection and Quarantine of the People’ s Republic of China. 2002. Basic standards for protection against ionizing radiation and for the safety of radiation sources: GB 18871. Beijing: Standards Press of China.
State Bureau of Environment Protection, General Administration of Quality Supervision, Inspection and Quarantine. 2005. Discharge Standard of water pollutants for medical organization: GB 18846. Beijing: Standards Press of China.
ICRP. 1991. Recommendations of the International Commission on Radiological Protection. ICRP Publication 60. Oxford: Pergamon Press.
ICRP. 2004. Release of Patients after Therapy with Unsealed Radionuclides. Ann. ICRP 34. DOI: 10.1016 / j. icrp. 2004.08.001
International Atomic Energy Agency, Pan American Health Organization, World Health Organization. 2002. Radiological Protection for Medical Exposure to Ionizing Radiation: IAEA Safety Standards Series No. RS-G-1. 5. Vienna: International Atomic Energy Agency.
Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, Schmidt MA, Bugaj JL, de Jong M, Krenning EP. 2001. [ 177Lu-DOTA0, Tyr3 ] octreotate: comparison with [ 111In-DTPA0 ] octreotide in patients. Eur J Nucl Med 28: 1319 – 1325.
Levart D, Kalogianni E, Corcoran B, et al. 2019. Radiation precautions for inpatient and outpatient 177 Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours. EJNMMI Phys 6: 7 – 7.
Ministry of Ecology and Environment of the People’ s Republic of China. 2021. Radiation Protection and Safety Requirements for Nuclear Medicine: HJ1188— 2021. Beijing: Environmental Science Press.
US Nuclear Regulatory Commission. 1997. Regulatory Guide 8. 39, Release of Patients Administered Radioactive Materials. Washington, DC: US Government Printing Office.
Ward WF. 2006. Basic principles of radiation biology. In: Henkin R. E., Bova D., Dillehay G. L. et al.( Eds.) Nuclear Medicine pp. 507-522. Philadelphia: MOSBY ELSEVIER.
Wyszomirska A. 2012. Iodine-131 for therapy of thyroid diseases. Physical and biological basis. Nuclear Medicine Review for Central and Eastern Europe 15: 120 – 123.
Zaknun JJ, Bodei L, Mueller-Brand J et al. 2013. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy( PRRNT) in neuroendocrine tumours. Eur J Nucl Med Molec Imag 40: 800 – 816. Cite this article as: Yunwen G. 2025. Determination of decay tank capacity and minimum storage time for liquid radioactive effluent based on environmental requirements. Radioprotection 60( 1): 91 – 98. https:// doi. org / 10.1051 / radiopro / 2024042